Table 1. Cohort description.
| all patients | MS with short duration | MS with long duration | |
|---|---|---|---|
| n | 28 | 17 | 11 |
| Gender [n = female] § | 11 | 8 | 3 |
| Age [years] mean±SD, range $ | 34.8±8.0, 19–55 | 30.7±6.1, 19–43 | 41±6.6, 33–55 |
| Time since first symptoms [months] mean±SD, range | 69±69,2–201 | 20±18,2–58 | 144±47,62–201 |
| EDSS median, range | 1.5, 0–7.0 | 1.5, 0–3 | 1.5, 1–7 |
| T2*w lesion count [n],mean±SD, range | 7.11±7.28,0–26 | 5.12±6.81,0–26 | 9.55±7.49,1–21 |
| T1 hypointense lesion count [n], mean±SD, range | 7.11±7.28,0–26 | 5.12±6.81,0–26 | 9.55±7.49,1–21 |
| SWI lesion count [n], mean±SD, range | 6.04±7.37,0–26 | 4.59±6.59,0–26 | 8.5±8.32,1–21 |
| Magnitude lesion count [n], mean±SD, range | 5.93±7.31,0–26 | 4.29±6.41,0–26 | 8.7±8.22,1–21 |
| Phase lesion count [n], mean±SD, range | 4.67±5.46,0–20 | 4.17±4.91,0–15 | 5.5±6.47,0–20 |
| Phase visibility [%], mean±SD, range # | 74.3±33,0–100 | 90±19.51,50–100 | 51±37,0–100 |
Patient-wise analysis. Key: MS with short duration: MS patients with less than 5 years disease duration; MS with long duration: MS patients with more than 5 years disease duration; SD: standard deviation
§ p = 0.295, Pearson’s Chi-squared test to assess gender differences between MS with short and long duration.
$ p<0.001, Kruskal-Wallis test to assess age differences between MS with short and long duration.
# p = 0.003, Mann-Whitney U test to assess group differences between MS with short and long duration.